Perlmutter’s Eikon follows the IPO trail

[ad_1] Former MSD head of R&D Roger Perlmutter has continued the swift development track for cancer start-up Eikon Therapeutics, filing an IPO to build its already healthy cash position further. Eikon has raised more than $1 billion since quietly launching in 2019, most recently with its $351 million Series D last year, and is now…

Read More